Hexetidine

Hexetidine (NSC-17764) is an orally active antibacterial and antifungal agent with broad antibacterial and antifungal activity. Hexetidine combined with IPBC potentiates strong fungal growth inhibition properties. Hexetidine at concentrations greater than 0.1% can cause oral ulceration. Additionally, Hexetidine improves its plaque inhibiting activities combined with zinc and has been confirmed the effectiveness on purulent wound along with ultrasound. Hexetidine is a promising candidate for research in fungus-related diseases and soft tissue purulent-inflammatory^{[1][2][3][4][5]} In Vitro:Hexetidine (15 μM, 14 days) retains strong inhibition of T. virens growth after incorporation within the alginate gel combined with iodopropynyl-butyl-carbamate (IPBC) (250 μg/ml)^[1].
Hexetidine (1 mg/ml, 2 h) exhibits the rates of kill similar for both S. aureus and Ps. aeruginosa with no detectable survivors in either growth phase within 2 h of contact^[6].
In Vivo:Hexetidine (0.5 g, p.o., 15-19 days) shows significantly better effectiveness on a purulent wound of rats combined with photoditazine s than their isolated use^[4].